Full-Time
Senior Specialist
Evidence Evaluation
Updated on 8/1/2026
Smith+Nephew
10,001+ employees
Global medical devices for orthopedics
No salary listed
United Kingdom
Hybrid
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to Smith+Nephew
See people who can refer or advise you
- Strong experience in medical or scientific writing, with the ability to critically appraise and synthesise clinical evidence in line with EU Medical Device Regulation and other related guidance.
- A solid understanding of clinical evaluation processes, literature review methodologies and benefit-risk assessment within medical devices or a closely related regulated environment.
- The confidence to act as a subject matter expert, engaging with cross-functional teams and supporting regulatory interactions, audits and submissions.
- A proactive and organised approach, with the ability to manage complex documentation, deadlines and priorities independently while working as part of a collaborative team.
- Bring together scientific expertise, medical writing and regulatory understanding to create robust clinical evidence documentation that underpins the continued CE registration of Smith+Nephew products.
- Immerse yourself in clinical data, literature and post-market insights, translating complex information into clear, high-quality documentation that demonstrates product safety and performance.
- Work closely with cross-functional partners as a trusted subject matter expert, supporting audits, submissions and strategic business decisions that determine whether products can be placed on the market and how they evolve over time.
Smith+Nephew is a global medical technology company that designs and makes medical devices for orthopaedics, sports medicine, and advanced wound care. Its products help surgeons treat joints and soft tissues and support patient recovery, including knee repair systems, single-use negative pressure wound therapy devices, and other extremity orthopaedic products. These devices are used in hospitals and clinics to perform procedures and support healing, often after surgery or injury. The company differentiates itself with a broad, worldwide product portfolio and collaborations with healthcare organizations to improve care and efficiency for patients and providers. Its goal is to improve patient outcomes, streamline medical procedures, and expand access to advanced medical solutions around the world.
Company Size
10,001+
Company Stage
IPO
Headquarters
Watford, United Kingdom
Founded
1856
Get referred to Smith+Nephew
See people who can refer or advise you
Simplify's Take
What believers are saying
- ASC Solutions can deepen relationships with physician groups and health systems.
- CORI XT clinical cases support broader adoption in knee and shoulder arthroplasty.
- Global operations across ~100 countries support commercial reach and product distribution.[6]
What critics are saying
- Stryker, Zimmer Biomet, and Johnson & Johnson can slow robotics share gains.
- ASC buildouts depend on capital budgets and vendor-standardization decisions.
- Robotics adoption remains vulnerable to training, workflow, and reliability failures.
What makes Smith+Nephew unique
- Smith+Nephew focuses on soft and hard tissue repair across orthopaedics, sports medicine, and wound care.[1][6]
- ASC Solutions bundles facility design, construction, financing, and clinical enablement into one platform.
- CORI XT is a handheld robotics platform built for both hospital and ASC procedures.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Holidays
Flexible Work Hours
Parental Leave
Fertility Treatment Support
Family Planning Benefits
Tuition Reimbursement
Wellness Program
Mental Health Support
Volunteer Time Off
Home Office Stipend
Phone/Internet Stipend
Discounted Stock Options
Health Savings Account/Flexible Spending Account
Employee Assistance Program
PTO/vacation?
Paid Sick Leave
Company News
Smith & Nephew reported strong full-year 2025 results, with revenue of $6.2 billion representing 5.3% underlying growth and 6.1% reported growth. Fourth-quarter revenue reached $1.7 billion, growing 6.2% on an underlying basis. The medical device company achieved 160 basis points of margin expansion, with trading profit of $1.2 billion and adjusted earnings per share of $1.02, up 21%. Free cash flow increased 52.5% year-on-year to $840 million, enabling completion of a $500 million share buyback programme. Innovation drove over 60% of growth, with products launched in the past five years delivering double-digit growth across all business units. For 2026, the company expects 6% organic revenue growth and 8% trading profit growth to around $1.3 billion, though it faces headwinds from Chinese pricing reforms and US reimbursement changes.
Smith+Nephew has signed an exclusive US distribution agreement with RMR Ortho to add the A'TOMIC Nitinol Fixation System to its Trauma, Foot & Ankle and Hand & Wrist portfolio. The partnership enables Smith+Nephew to expand its participation in high-frequency fracture and arthrodesis procedures whilst utilising its existing Extremities and Trauma sales channel. The dynamic compression fixation solution complements the company's current technologies. Scott Gunn, Vice President of US Marketing at Smith+Nephew, said the collaboration reflects the company's disciplined approach to portfolio expansion and continued focus on driving sustainable growth.
Smith+Nephew has acquired Integrity Orthopaedics for an initial $225 million cash payment, plus up to $225 million in performance-based payments over five years. The deal strengthens Smith+Nephew's sports medicine portfolio with the Tendon Seam rotator cuff repair technology. Founded in 2020, Integrity Orthopaedics developed the innovative system to address high failure rates in traditional rotator cuff repairs. The technology uses patented micro-anchors and continuous suture designed to deliver stronger repairs and lower re-tear rates. Early clinical results show reduced pain and shorter recovery times. The rotator cuff repair market performs approximately 500,000 procedures annually in the US, valued at $875 million. The acquisition, expected to close by end of January 2026, will be financed from existing cash facilities and is expected to be accretive to trading profit margin by 2028.
Download the Swiss reference publication on investments, investors and exits in our assets section.
Smith+Nephew to showcase advanced Orthopaedic Reconstruction technologies for robotics, knees, hips, and shoulders at AAOS 2025.